Matrivax is proud to announce that Enda Moran, Ph.D., M.B.A., has joined Matrivax as Vice President of Process Development and CMC. Enda comes to Matrivax with more than two decades of manufacturing, process development, and CMC management across the USA and Europe, most notably with Wyeth/Pfizer and GSK in vaccines and biologics. Enda's experience will support Matrivax's evolution into a clinical-stage, high-value vaccine development company.
Welcome, Enda!
Updated: Sep 16, 2020
Come hear our Dr. Kevin Killeen give an update on our pneumococcal vaccine at the Vaccine Technology Summit 2020 on Dec 9-10th.
We are excited to announce that Ed Mascioli, M.D. has joined Matrivax as Chief Executive Officer (CEO) and Member of the Board of Directors. Dr. Mascioli is an experienced pharmaceutical and venture executive, and has held senior executive positions at Pfizer, Dapis Capital, Peptimmune, MPM Capital, Karos and Affinium. His leadership and business development expertise will be key in advancing our vaccine candidates through the clinic. Together, we look forward to developing our programs and building new partnerships. Welcome to the Matrivax team, Dr. Mascioli!